These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15530292)

  • 41. Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy.
    Calmy A; Carey D; Mallon PW; Wand H; Law M; Cooper DA; Carr A; ;
    HIV Med; 2008 Feb; 9(2):101-10. PubMed ID: 18257772
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A multicenter, 47-month study of safety and efficacy of calcium hydroxylapatite for soft tissue augmentation of nasolabial folds and other areas of the face.
    Sadick NS; Katz BE; Roy D
    Dermatol Surg; 2007 Dec; 33 Suppl 2():S122-6; discussion S126-7. PubMed ID: 18086049
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.
    Sutinen J; Walker UA; Sevastianova K; Klinker H; Häkkinen AM; Ristola M; Yki-Järvinen H
    Antivir Ther; 2007; 12(1):97-105. PubMed ID: 17503753
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact on weight and height with the use of HAART in HIV-infected children.
    Guillén S; Ramos JT; Resino R; Bellón JM; Muñoz MA
    Pediatr Infect Dis J; 2007 Apr; 26(4):334-8. PubMed ID: 17414398
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bone mineral and soft-tissue changes in AIDS-associated lipoatrophy.
    Rosenthall L; Falutz J
    J Bone Miner Metab; 2005; 23(1):53-7. PubMed ID: 15616895
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients.
    Loutfy MR; Raboud JM; Antoniou T; Kovacs C; Shen S; Halpenny R; Ellenor D; Ezekiel D; Zhao A; Beninger F
    AIDS; 2007 May; 21(9):1147-55. PubMed ID: 17502725
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of injectable CaHA for the treatment of mid-face volume loss.
    Beer K; Yohn M; Cohen JL
    J Drugs Dermatol; 2008 Apr; 7(4):359-66. PubMed ID: 18459517
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV- 1/HAART-associated lipodystrophy.
    Giralt M; Domingo P; Guallar JP; Rodriguez de la Concepción ML; Alegre M; Domingo JC; Villarroya F
    Antivir Ther; 2006; 11(6):729-40. PubMed ID: 17310817
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A multicenter, randomized trial comparing calcium hydroxylapatite to two hyaluronic acids for treatment of nasolabial folds.
    Moers-Carpi M; Vogt S; Santos BM; Planas J; Vallve SR; Howell DJ
    Dermatol Surg; 2007 Dec; 33 Suppl 2():S144-51. PubMed ID: 18086052
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Facial lipoatrophy secondary to a new synthetic filler device (Profill) treated by lipofilling.
    André P
    J Cosmet Dermatol; 2002 Jul; 1(2):59-61. PubMed ID: 17147520
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Polymethylmethacrylate facial implant: a successful personal experience in Brazil for more than 9 years.
    Carvalho Costa IM; Salaro CP; Costa MC
    Dermatol Surg; 2009 Aug; 35(8):1221-7. PubMed ID: 19438669
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sculptra (injectable poly-L-lactic acid).
    Keni SP; Sidle DM
    Facial Plast Surg Clin North Am; 2007 Feb; 15(1):91-7, vii. PubMed ID: 17317560
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Facial lipoatrophy: appearances are not deceiving.
    Sanches RS; Mill J; Machado AA; Donadi EA; Morais Fernandes AP
    J Assoc Nurses AIDS Care; 2009; 20(3):169-75. PubMed ID: 19427594
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Infectious complications of Bio-Alcamid filler used for HIV-related facial lipoatrophy.
    Nadarajah JT; Collins M; Raboud J; Su D; Rao K; Loutfy MR; Walmsley S
    Clin Infect Dis; 2012 Dec; 55(11):1568-74. PubMed ID: 22942210
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Calcium hydroxylapatite: Radiesse.
    Ahn MS
    Facial Plast Surg Clin North Am; 2007 Feb; 15(1):85-90, vii. PubMed ID: 17317559
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dyslipidemia and lipodystrophy in HIV-infected Thai children on highly active antiretroviral therapy (HAART).
    Lapphra K; Vanprapar N; Phongsamart W; Chearskul P; Chokephaibulkit K
    J Med Assoc Thai; 2005 Jul; 88(7):956-66. PubMed ID: 16241026
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Idiopathic hemi-facial lipoatrophy treated with autologous fat transfer.
    Liu SW; Cohen GF
    J Cosmet Dermatol; 2010 Sep; 9(3):226-9. PubMed ID: 20883296
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An index for staging facial lipoatrophy and evaluation of the efficacy of the treatment with polymethylmethacrylate in HIV/AIDS patients: a pilot study.
    Serra MS; Oyafuso LK; Trope BM; Munhoz Leite OH; Ramos-e-Silva M
    J Eur Acad Dermatol Venereol; 2013 Aug; 27(8):990-6. PubMed ID: 22774979
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of the Radiance FN soft tissue filler for facial soft tissue augmentation.
    Tzikas TL
    Arch Facial Plast Surg; 2004; 6(4):234-9. PubMed ID: 15262717
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HIV lipoatrophy and mosquito bites.
    Greub G; Fellay J; Telenti A
    Clin Infect Dis; 2002 Jan; 34(2):288-9. PubMed ID: 11740720
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.